Aquestive Therapeutics (NASDAQ:AQST) Earns Market Outperform Rating from JMP Securities

JMP Securities reissued their market outperform rating on shares of Aquestive Therapeutics (NASDAQ:AQST) in a research note issued to investors on Tuesday morning, Benzinga reports. JMP Securities currently has a $9.00 target price on the stock.

A number of other brokerages have also recently weighed in on AQST. HC Wainwright increased their price target on shares of Aquestive Therapeutics from $9.00 to $10.00 and gave the stock a buy rating in a research note on Monday, September 30th. Leerink Partners reiterated an outperform rating and set a $12.00 target price (up previously from $10.00) on shares of Aquestive Therapeutics in a research note on Monday, September 30th. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of Buy and a consensus target price of $8.67.

Aquestive Therapeutics Price Performance

NASDAQ AQST opened at $4.89 on Tuesday. The company has a fifty day moving average of $4.47 and a two-hundred day moving average of $3.70. The company has a market capitalization of $445.28 million, a PE ratio of -13.97 and a beta of 2.85. Aquestive Therapeutics has a 1 year low of $1.35 and a 1 year high of $6.23.

Aquestive Therapeutics (NASDAQ:AQST) last released its quarterly earnings results on Tuesday, August 6th. The company reported ($0.03) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.08. The firm had revenue of $20.10 million for the quarter, compared to analysts’ expectations of $12.62 million. During the same quarter in the prior year, the business earned ($0.10) EPS. On average, research analysts expect that Aquestive Therapeutics will post -0.48 earnings per share for the current year.

Institutional Trading of Aquestive Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in AQST. Victory Capital Management Inc. acquired a new position in Aquestive Therapeutics during the 2nd quarter worth approximately $27,000. SG Americas Securities LLC purchased a new stake in shares of Aquestive Therapeutics in the first quarter valued at approximately $54,000. Lazard Asset Management LLC grew its holdings in Aquestive Therapeutics by 115.5% during the first quarter. Lazard Asset Management LLC now owns 29,112 shares of the company’s stock worth $124,000 after acquiring an additional 15,601 shares during the period. The Manufacturers Life Insurance Company purchased a new position in Aquestive Therapeutics in the second quarter worth $76,000. Finally, Financial Advocates Investment Management lifted its holdings in Aquestive Therapeutics by 70.0% in the second quarter. Financial Advocates Investment Management now owns 34,000 shares of the company’s stock valued at $88,000 after acquiring an additional 14,000 shares during the period. Hedge funds and other institutional investors own 32.45% of the company’s stock.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.